Wegovy
60 articles on Wegovy, written by Shotlee and medically reviewed for clinical accuracy.
Wegovy Side Effects: Black Tongue, Pain, Gallbladder Removal in Woman's Story
A 32-year-old bride-to-be turned to Wegovy for wedding weight loss, only to face black tongue, unbearable stomach pain, and gallbladder removal. Sarah-Jayne Crawford's ordeal highlights hidden dangers of semaglutide injections. Despite initial success, severe side effects led to emergency surgery.
6 min read
EU Approves Easier Wegovy Delivery, Easing Cold Chain Rules
Novo Nordisk has won EU regulatory approval to ease cold chain requirements for Wegovy injections, marking the first GLP-1 therapy in Europe with such delivery flexibility. The change allows a 48-hour window without refrigeration from pharmacies to patients, streamlining distribution and enhancing access. This aligns with trends in direct-to-patient models and complements recent subscription programs for better affordability.
5 min read
Doctor Warns of 'Miserable' Constipation from Wegovy as NHS Expands to 1.2M
The NHS has expanded free Wegovy access to 1.2 million more people, but a doctor is urging caution over a 'miserable' side effect: constipation. Dr. Suraj Kukadia explains how GLP-1 medications like Wegovy slow digestion, leading to this common issue. Discover the mechanism and tips for those considering these weight loss jabs.
5 min read
GLP-1 Weight-Loss Drugs Face Bone Health Risks in Older Adults
Emerging research is raising questions about GLP-1 weight-loss drugs like Ozempic and Wegovy, showing a potential link to bone loss and fractures in older adults. A major study in the Journal of Clinical Endocrinology & Metabolism found higher fragility fracture risks among seniors on these medications. Experts stress monitoring and preventive steps to balance benefits with bone protection.
5 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
Wegovy's New Subscription Saves Up to $1,200/Year – Not for Everyone
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
4 min read
Wegovy Linked to Sudden Vision Loss Risk, Study Finds
Researchers analyzing over 30 million FDA safety reports found Wegovy associated with nearly five times higher odds of ischemic optic neuropathy (ION), or 'eye stroke,' compared to Ozempic. This sudden vision loss risk was strongest in men on Wegovy. While rare, these findings urge caution and further study for GLP-1 users.
5 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
5 min read
Novo Nordisk's FDA-Approved GLP-1s Now on Hims & Hers
Hims & Hers Health, Inc. has partnered with Novo Nordisk to bring a broad assortment of FDA-approved GLP-1 medications to eligible customers, including the groundbreaking Wegovy® pill. This collaboration simplifies access with affordable prices, expanded doses, and diverse delivery methods. As the largest global consumer health platform for these approved meds, Hims & Hers is transforming weight management options.
4 min read
Traveling with GLP-1s Like Wegovy: Key Tips Before Flying
More people are using GLP-1 injectables like Wegovy for weight management, but air travel poses refrigeration challenges. As a flight attendant, I've fielded countless requests to store meds in plane fridges—here's why that's not possible and the practical solutions that work.
5 min read
FDA Approves Triple Max Dose of Wegovy: 7.2mg Now Available
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
5 min read
GLP-1 Microdosers Chase Longevity: Survey Insights
More than 10% of U.S. adults use GLP-1 drugs like Ozempic and Wegovy, but one in seven microdose for longevity without major weight loss or side effects, per Evidation survey. Biohackers and clinics like AgelessRx promote it for reducing inflammation and chronic disease risks. Yet experts caution on unproven claims and sourcing risks.
5 min read
Hims & Hers Opens $149 Wegovy & Ozempic Waitlist via Novo Deal
Hims & Hers Health (NYSE: HIMS) is now offering a waitlist for affordable branded Wegovy and Ozempic at $149, thanks to a new Novo Nordisk deal. This expands access to these popular GLP-1 weight-loss drugs amid high demand. Meanwhile, HIMS stock shows short-term rebound potential in a downtrend—dive into the technicals and analyst views.
5 min read
Study: Wegovy Vision Loss Risk 5x Higher Than Ozempic
A groundbreaking study reveals Wegovy carries a fivefold higher risk of vision-threatening ischemic optic neuropathy compared to Ozempic. Analyzing millions of FDA reports, researchers link the risk to semaglutide's higher doses in Wegovy. Amid rising lawsuits, patients need to weigh benefits against potential eye health dangers.
5 min read
Weight Loss Injections Side Effects Affect 1 in 10 Users
Weight loss injections such as Mounjaro and Wegovy, popular GLP-1 inhibitors, come with side effects impacting one in 10 users, primarily digestive issues like nausea and diarrhea. The British Heart Foundation highlights risks including pancreatitis, vision loss, and nutritional deficiencies. Understanding these helps patients manage treatment safely.
5 min read
Novo Crash Cuts Wegovy Maker Shareholder Assets by a Third
Novo Nordisk A/S's dramatic stock slump has reduced controlling shareholder Novo Holdings' assets by about a third to 694 billion Danish kroner ($108 billion). Facing cheaper copycats and Eli Lilly rivalry, the Wegovy maker confronts steep sales declines. Despite challenges, the fund posted 9% returns.
5 min read
What Happens After Stopping GLP-1 Drugs Like Ozempic? UK Study Findings
A new Cambridge study reveals that after stopping GLP-1 drugs like Ozempic and Wegovy, patients regain nearly 60% of lost weight within a year, with appetite returning rapidly. Researchers modeled long-term trends showing about 75% regain over time, emphasizing the need for lifestyle support. This comprehensive guide breaks down the findings and what they mean for patients.
6 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
Study Finds Some Patients Keep Weight Off with Fewer GLP-1 Injections
A new study shows that some patients on GLP-1 drugs like Wegovy can space out injections every other week or longer and still keep weight off. Led by Dr. Mitch Biermann at Scripps Clinic, the research followed 34 patients who maintained health gains after reducing frequency. Experts say this reframes long-term obesity treatment discussions.
5 min read
Denmark's Obesity Rate Stalls in Wegovy-Maker Novo's Home Market
Obesity levels have plateaued in Denmark at 18.5% among adults and older teens in 2025, unchanged from 2021 after years of rises from 13.6% in 2010. Novo Nordisk launched Wegovy there in late 2022, with 270,000 users—nearly 5% of the population—potentially shifting trends away from 32% by 2040 projections. Experts credit GLP-1 drugs like Wegovy and Ozempic alongside lifestyle factors.
4 min read
Beyond Weight Loss: Ozempic Linked to Migraine Reduction, Study
GLP-1 receptor agonists like Ozempic, used for diabetes and weight loss, may offer relief for chronic migraine sufferers by cutting emergency department visits and medication needs. A new study compares them to topiramate, revealing promising associations in stabilizing migraine burden. Presented at the American Academy of Neurology's 2026 meeting, these findings highlight unexpected benefits beyond weight loss.
5 min read
Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
5 min read
Novo's Woes Despite Ozempic's Explosive Growth
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
5 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
Novo Nordisk Slashes Wegovy Prices 50%, Ozempic 35% in 2027
Novo Nordisk is dramatically reducing prices for its blockbuster GLP-1 drugs, slashing Wegovy by 50% and Ozempic by 35% to $675 per month starting in January 2027. This move addresses calls for affordability from patients and payers facing high-deductible plans. Amid fierce competition from Eli Lilly's Mounjaro and Zepbound, these cuts could broaden access to these transformative medications.
5 min read
US May Fine Hims for Brief Wegovy Compounded Launch
Hims & Hers briefly launched a $49 compounded version of Novo Nordisk's Wegovy, prompting swift FDA backlash and a DOJ referral. Experts say the US could impose fines or injunctions for violating drug laws, though Hims' quick retreat might limit action. This highlights tensions between compounded GLP-1s and approved weight-loss drugs amid surging demand.
5 min read
Wegovy's Weight Loss Hype Meets Reality: What Americans Should Know
Wegovy's explosion on TikTok and US headlines promises dramatic weight loss, but the reality involves high costs, pharmacy shortages, and the need for medical supervision. As a higher-dose semaglutide GLP-1 agonist approved for obesity, it offers double-digit weight loss in trials—but stopping it often leads to regain. US experts urge viewing it as chronic disease management, not a casual 'slimming trend.'
6 min read
Study: Ozempic, Wegovy NAION Risk Twofold Higher vs. SGLT2i Drugs
New research from Veterans' Affairs shows Ozempic and Wegovy users face double the risk of NAION—a serious vision loss condition—compared to SGLT2i drugs. Published in JAMA Ophthalmology, the study urges doctors to warn patients about potential permanent blindness from semaglutide-based GLP-1 medications. As lawsuits mount, understand the implications for diabetes and weight management.
5 min read
Dr Reddy's Wegovy Generic Set for 50-60% Discounts in India
Indian drugmaker Dr Reddy's Laboratories is gearing up to launch a generic version of Novo Nordisk's Wegovy at prices up to 60% lower than the original. Co-chairman G V Prasad confirmed 50-60% discounts are feasible as semaglutide's patent nears expiry in March. This could reshape access to weight-loss treatments in India's competitive market.
5 min read
Lee Soon-sil's 30kg Wegovy Weight Loss Shines in Hanbok
South Korean chef and broadcaster Lee Soon-sil turned heads in a fitted hanbok on KBS1's Morning Maze, revealing her impressive 30kg weight loss achieved with Wegovy. Her husband Hwang Yoo-sung couldn't hide his admiration, calling her 'so pretty.' This heartfelt TV moment highlights real-world Wegovy success in metabolic health.
5 min read
Novo Nordisk to Meet US Wegovy Pill Demand First, CEO Doustdar Says
Novo Nordisk is prioritizing the US market for its popular Wegovy pill to prevent shortages like those seen with injectable semaglutide. CEO Mike Doustdar emphasized a country-by-country rollout strategy amid legal battles against compounders and competition from Eli Lilly. With 246,000 US users already on the oral obesity drug, supply stability is key.
5 min read
McDonald's Execs Plan for More GLP-1 Customers Like Ozempic Users
McDonald's executives revealed plans to cater to the growing number of customers on GLP-1 drugs like Ozempic during their latest earnings call. With users seeking high-protein options and avoiding sugary drinks, the chain is testing menu tweaks. This shift reflects broader changes in the food industry as GLP-1 adoption hits 10% of the US population.
6 min read
Meijer Reduces Out-of-Pocket Costs for GLP-1 Meds Like Ozempic, Wegovy
Meijer is making GLP-1 medications more affordable by accepting manufacturer savings programs for Ozempic and Wegovy, dropping costs to $199 per month for the first two months on lowest doses. The retailer also offers the newly approved oral Wegovy through the same program, starting at $149 out-of-pocket. This move aims to boost access to these popular weight loss injections amid rising demand.
5 min read
Hims Stops Compounded Wegovy Pill After FDA Scrutiny
Telehealth giant Hims & Hers has abruptly stopped offering its newly launched compounded version of Novo Nordisk's Wegovy pill amid FDA scrutiny. The decision follows constructive industry conversations, raising questions about compounded GLP-1 availability. Patients seeking semaglutide for weight management now face shifting options.
5 min read
HIMS Shares Sink After FDA Vows Swift Action on Copycat GLP-1 Drugs
Hims & Hers Health's bold launch of a $49-per-month copycat GLP-1 pill to rival Wegovy's $149 price tag backfired spectacularly. FDA Commissioner Marty Makary vowed 'swift action' against such unapproved drugs, sending HIMS shares down 7.5% in premarket trading. This regulatory showdown highlights growing tensions in the GLP-1 market dominated by Novo Nordisk and Eli Lilly.
4 min read
Novo Nordisk Shares Rebound as FDA Targets Illegal Wegovy Copies
Novo Nordisk's shares rebounded 4.7% in early trading on Friday after the FDA vowed to crack down on companies mass-marketing illegal copies of Wegovy. This followed a sharp sell-off triggered by Hims & Hers' launch of a cheap $49 compounded version. Understand the safety risks and what this means for GLP-1 patients seeking approved weight-loss treatments.
5 min read
Child Ozempic Overdose: Risks, Symptoms & Prevention Guide
When 7-year-old Jessa injected her mom's Ozempic thinking it was stomach medicine, she faced severe vomiting, dehydration, and kidney risks. This incident underscores the dangers of GLP-1 medications like semaglutide and tirzepatide in children. Discover prevention tips and what to do in an emergency.
4 min read
Wegovy Pill Hits 26K Prescriptions in Week 2: Launch Breakdown
Novo Nordisk's new Wegovy pill has exploded onto the scene, racking up over 26,000 prescriptions in just its second full week. This needle-free GLP-1 option signals a shift in obesity treatment. Discover the data, science, and patient implications behind this rapid uptake.
4 min read
What Happens When You Stop Ozempic or Wegovy: Expert Insights
Stopping Ozempic or Wegovy often leads to significant weight regain within 1-1.5 years, reversing gains in blood sugar, pressure, and cholesterol. Experts explain the science behind this, from metabolic adaptation to surging appetite. Understand how to approach GLP-1 therapy for long-term success.
4 min read
Saccharine: Horror Lessons on GLP-1 Weight Loss Realities
The chilling film 'Saccharine' imagines a diet pill worse than Ozempic—made from human ashes. But what does it reveal about real GLP-1 weight loss drugs? This guide dives into the science, psychological pitfalls, and evidence-based tips for safe use.
4 min read
Higher-Dose Wegovy: NHS Trials, Real Results & Safety
The NHS has approved a triple-strength 7.2mg Wegovy dose, promising greater weight loss for those plateauing on standard semaglutide. One user's story highlights the frustration of switching from Mounjaro due to costs, sparking debate on higher GLP-1 doses. Discover the science, safety, and what it means for metabolic health.
5 min read
Novo Nordisk Pushes Consumer-Friendly Wegovy Pill
Novo Nordisk ramps up direct-to-consumer access to its new daily Wegovy pill through NovoCare's redesign and telehealth ties. Berenberg analysts see rising demand from consumers seeking speed and privacy over traditional clinics. This shift makes GLP-1 weight loss treatment feel like online shopping.
1 min read
Wegovy Pill: 18,410 Prescriptions in First Full Week
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its first full week after launch, surpassing other GLP-1 starts. Investors eye its edge over Eli Lilly in the competitive obesity market. Oral treatments offer needle-free flexibility for patients.
1 min read
New Data: Little Weight Rebound After Stopping Ozempic, Wegovy
New research challenges fears of quick weight regain after stopping GLP-1 drugs like Ozempic and Wegovy. Real-world data reveals many patients sustain their losses. Experts say durability is possible without lifelong treatment.
1 min read
Sun Pharma Approved for Generic Wegovy in India
Sun Pharmaceutical Industries secures approval to manufacture and sell generic Wegovy in India. The generic semaglutide, branded Noveltreat, launches after March 2026 patent expiry. Indian firms race to tap the booming GLP-1 weight loss market.
1 min read
Seoul Hoards 66% of GLP-1 Supply as High-Risk Areas Lack
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
2 min read
GLP-1 Drugs Save Airlines $580M Yearly in Fuel Costs
Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.
2 min read
South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
4 min read
Prof Urges Caution on Funding Wegovy Rollout
Prof Jim Mann cautions against broad funding for Wegovy, urging focus on high-risk patients like those with heart disease or diabetes. He emphasizes integrating GLP-1 medications into a national obesity strategy with mandatory nutritional support to prevent weight regain. Early data highlights side effect risks and the need for dietary counseling.
2 min read
GLP-1 Drugs Force Restaurant Chains to Shrink Menus
GLP-1 weight loss drugs like Ozempic and Wegovy are transforming restaurant menus. Major chains now provide smaller servings and protein-rich items as users eat less but prioritize quality. A recent poll shows 12% of Americans on these medications.
1 min read
Specialist: Funding Wegovy Saves Taxpayer Money Long-Term
Pharmac is evaluating funding for Wegovy, a GLP-1 receptor agonist, to combat New Zealand's high obesity rates. Weight loss specialist Dr. Gerard McQuinlan says it could save taxpayers billions by preventing diseases like Type 2 diabetes. Experts weigh long-term costs, side effects, and criteria.
2 min read
GLP-1 Drugs Reshaping Eating Habits in Connecticut
GLP-1 weight-loss drugs like Ozempic and Wegovy are changing how people in Connecticut eat, boosting demand for protein-rich foods to combat muscle loss. Nutrition experts and restaurateurs note shifts toward balanced meals and smaller portions. A clinical epidemiologist reveals how these drugs suppress appetite and delay gastric emptying for significant weight reduction.
4 min read
Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed
Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.
2 min read
Wegovy Pill vs Injections: Which is Right for You?
Semaglutide injections like Ozempic and Wegovy offer weekly dosing for better adherence than daily pills like Rybelsus, especially for complex regimens or travel. A 2021 JAMA study confirms higher compliance with injections. Tailor your GLP-1 choice to individual needs for optimal results.
2 min read
Wegovy Recall: Hair in Syringes, Gold Star Droppings Issue
Novo Nordisk recalled Wegovy pens after FDA inspectors found hair particles in prefilled syringes. Gold Star Distribution issued a broad recall due to rodent feces and droppings in storage. These Class II recalls highlight contamination risks in GLP-1 medications and pharma supply chains.
3 min read
Pharmac Seeks Advice on Funding Wegovy Weight Loss Drug
New Zealand faces the third-highest adult obesity rate in the OECD, prompting Pharmac to seek clinical advice on funding Wegovy. Two applications propose semaglutide for high-BMI patients with cardiovascular risks or comorbidities. Experts argue it could save billions by preventing diseases like Type 2 diabetes.
2 min read
Novo's Wegovy Oral Pill Shows Strong Early US Momentum vs Lilly
Novo Nordisk's new oral Wegovy pill achieved 3,071 retail prescriptions in its first four days in the US. This strong start signals competition with Eli Lilly's offerings. Analysts predict up to $1 billion in 2024 sales if momentum continues.
1 min read
5 Things to Know Before Switching to Oral GLP-1 Pills
Oral GLP-1 medications offer a convenient alternative to weekly injections for weight loss. Discover the main differences in absorption, dosing, and routine. Follow these 5 tips to ensure a successful switch without losing progress.
2 min read
Experts Warn of Nutritional Gaps in Ozempic, Wegovy Users
Researchers from UCL and the University of Cambridge warn that Ozempic and Wegovy users risk nutritional deficiencies and muscle loss without proper dietary guidance. A study in Obesity Reviews reveals limited evidence on nutrition alongside GLP-1 drugs like semaglutide and tirzepatide. Experts urge structured support to ensure safe, sustainable weight loss.
4 min read
Cardiologist: GLP-1 Drugs Benefits Beyond Weight Loss for Heart, Liver
Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.
1 min read